Vincamine

Research use only, not for human use.

Vincamine is a peripheral vasodilator, that increases blood flow to the brain.

Vincamine is a peripheral vasodilator, that increases blood flow to the brain.(In Vitro):Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi?cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28?μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85?μM) in hGPR40-CHO cells.(In Vivo):Vincamine (intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion in vivo.

Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi?cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, ?after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28?μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85?μM) in hGPR40-CHO cells.

Vincamine (intraperitoneal injection; 15 and 30?mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion?in vivo.

Angiopac | Devincan | Equipur | Minorin | NSC 91998 | Novicet

Others

Other Targets

Others

Cardiovascular Disease

——

1617-90-9

354.44

C21H26N2O3

>98% (HPLC)

Water: 62 mg/L

O[C@@](C1)(C(OC)=O)N2C3=C(C=CC=C3)C4=C2[C@@]([C@@]1(CC)CCC5)([H])N5CC4

14,15-Dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester

(-20℃)

With Ice Pack

≥ 2 years